110 related articles for article (PubMed ID: 8549303)
1. In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Gaillot O; Berche P
Drugs; 1995; 49 Suppl 2():200-2. PubMed ID: 8549303
[No Abstract] [Full Text] [Related]
2. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Molinari G; Schito GC
Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
[No Abstract] [Full Text] [Related]
3. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
Lafredo SC; Foleno BD; Fu KP
Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
5. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of MF 5137, a new potent 6-aminoquinolone.
Wise R; Pagella PG; Cecchetti V; Fravolini A; Tabarrini O
Drugs; 1995; 49 Suppl 2():272-3. PubMed ID: 8549329
[No Abstract] [Full Text] [Related]
10. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Pérez-Giraldo C; Rodríguez-Benito A; Morán FJ; Hurtado C; Blanco MT; Gómez-García AC
J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
[No Abstract] [Full Text] [Related]
11. Susceptibility of microorganisms isolated from chronic suppurative otitis media to ciprofloxacin.
Altuntas A; Aslan A; Eren N; Unal A; Nalca Y
Eur Arch Otorhinolaryngol; 1996; 253(6):364-6. PubMed ID: 8858262
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Jones RN
Drugs; 1995; 49 Suppl 2():205-7. PubMed ID: 8549305
[No Abstract] [Full Text] [Related]
15. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
[TBL] [Abstract][Full Text] [Related]
16. Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1997 Apr; 39(4):549-50. PubMed ID: 9145831
[No Abstract] [Full Text] [Related]
17. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
Azadian BS; Talboys CA; Roberts AP
J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
[No Abstract] [Full Text] [Related]
18. Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.
Brumfitt W; Hamilton-Miller JM
J Antimicrob Chemother; 1993 Apr; 31(4):610-2. PubMed ID: 8390435
[No Abstract] [Full Text] [Related]
19. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of BAY Y 3118 against selected species.
Verbist L; Verhaegen J
Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326
[No Abstract] [Full Text] [Related]
[Next] [New Search]
